Travere Therapeutics (TVTX) legal chief sells shares in planned trade

Rhea-AI Filing Summary

Travere Therapeutics Chief Legal Officer Elizabeth E. Reed reported planned stock sales under a Rule 10b5-1 trading plan. On February 4, 2026, she sold 2,485 shares of common stock at a weighted average price of $32.07 and 509 shares at a weighted average price of $32.74.

The filing notes that the plan was adopted on June 16, 2025 and that the transactions include shares sold to cover tax obligations from vesting restricted stock units. After these sales, Reed directly owned 105,211 shares of Travere Therapeutics common stock.

Insider Trade Summary

Net Seller: 2,994 shares ($96,359)

Net Sell 2 txns

Insider REED ELIZABETH E

Role Chief Legal Officer and GC

Sold 2,994 shs ($96K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,485	$32.07	$80K
Sale	Common Stock	509	$32.74	$17K

Holdings After Transaction: Common Stock — 105,720 shares (Direct)

Footnotes (1)

1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. The weighted average sale price for the transaction reported was $32.07, and the range of prices were between $31.63 and $32.61. Upon request by the SEC staff, the Issuer, or any security holder of theIssuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $32.74, and the range of prices were between $32.64 and $32.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REED ELIZABETH E

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer and GC

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		S(1)		2,485	D	$32.07(2)	105,720	D
Common Stock	02/04/2026		S(1)		509	D	$32.74(3)	105,211	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $32.07, and the range of prices were between $31.63 and $32.61. Upon request by the SEC staff, the Issuer, or any security holder of theIssuer, full information regarding the number of shares sold at each price will be provided.

3. The weighted average sale price for the transaction reported was $32.74, and the range of prices were between $32.64 and $32.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Elizabeth E. Reed	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Elizabeth E. Reed report for Travere Therapeutics (TVTX)?

Elizabeth E. Reed, Chief Legal Officer of Travere Therapeutics, reported selling company common stock. She sold 2,485 shares at a weighted average price of $32.07 and 509 shares at $32.74, all in transactions dated February 4, 2026 under a pre-arranged trading plan.

How many Travere Therapeutics shares does Elizabeth E. Reed hold after this Form 4?

After the reported sales, Elizabeth E. Reed directly owns 105,211 shares of Travere Therapeutics common stock. This figure reflects her remaining beneficial ownership following the two February 4, 2026 transactions disclosed in the filing, where a total of 2,994 shares were sold.

Were Elizabeth E. Reed’s Travere Therapeutics stock sales made under a Rule 10b5-1 plan?

Yes. The filing states the sale was made pursuant to a written plan adopted June 16, 2025 that meets Rule 10b5-1(c) requirements. Such plans allow insiders to pre-schedule trades, helping separate personal trading decisions from day-to-day nonpublic corporate information.

What prices were received in Elizabeth E. Reed’s Travere Therapeutics share sales?

The first transaction had a weighted average sale price of $32.07, with individual trades between $31.63 and $32.61. The second had a weighted average of $32.74, with prices between $32.64 and $32.90, as disclosed for the February 4, 2026 sales.

Did the Travere Therapeutics insider sale include shares for tax withholding?

Yes. The filing explains that the sale includes shares sold to cover tax obligations arising upon the vesting of restricted stock units. This indicates that part of the reported share sales relates to satisfying associated tax liabilities triggered by equity compensation vesting.

Who is the insider in this Travere Therapeutics (TVTX) Form 4 and what is their role?

The insider is Elizabeth E. Reed, who serves as Chief Legal Officer and General Counsel of Travere Therapeutics. She is an officer but not listed as a director or 10% owner, and the reported transactions involve her directly held common stock holdings in the company.